Proposed research diagnostic criteria for neuroleptic malignant syndrome

International Journal of Neuropsychopharmacology

Volumn 2, Issue 2, 1999, Pages 129-144

  Adityanjee, ^a,c   Mathews, Thomas ^a   Aderibigbe, Yekeen A ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diagnostic criteria; Drug induced hyperthermic catatonia (DIHC); Hyperthermic catatonia; Incidence rates; Neuroleptic malignant syndrome (NMS); Neuroleptics; Research diagnosis

Indexed keywords

EID: 0001520199     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1461145799001388     Document Type: Article

References (136)

1. Abbot RJ, Loizou LA (1986). Neuroleptic malignant syndrome. British Journal of Psychiatry 148, 47-51.
2. Adityanjee (1987a). Neuroleptic malignant syndrome or lithium neurotoxicity (letter). British Journal of Psychiatry 150, 568-569.
3. Adityanjee (1987b). Diagnosing and defining neuroleptic malignant syndrome (letter). American Journal of Psychiatry 144, 1370-1371.
4. Adityanjee (1988). The spectrum concept and prevalence of neuroleptic malignant syndrome (letter). American Journal of Psychiatry 145, 1041.
5. Adityanjee (1991). The myth of elevated serum creatine phosphokinase level and malignant syndrome. British Journal of Psychiatry 158, 706-707.
6. Adityanjee, Aderibigbe YA, Mathews T (In Press). Epidemiology of neuroleptic malignant syndrome. Clinical Neuropharmacology.
7. Adityanjee, Das P, Chawla HM (1989). Neuroleptic malignant syndrome and psychotic illness. British Journal of Psychiatry 155, 852-854.
8. Adityanjee, Jayaswal SK, Chan SP, Subramaniam M (1992). Neuroleptic malignant syndrome in an elderly patient; problems in management. International Journal of Geriatric Psychiatry 7, 843-846.
9. Adityanjee, Singh S, Singh G, Ong S (1988). Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry 153, 107-111.
10. Addonizio G, Susman VL, Roth SD (1986). Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 143, 1587-1590.
11. Addonizio G, Susman VL, Roth SD (1987). Neuroleptic malignant syndrome: review and analysis of 115 cases. Biological Psychiatry 52, 102-104.
12. American Psychiatric Association (1994). Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders (4th ed.), Appendix B (pp. 739-742). Washington, DC: American Psychiatric Association.
13. Anderson ES, Powers PS (1991). Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry 52, 102-104.
14. Baker RW, Roy Chengappa KN (1995). Further study of neuroleptic malignant syndrome. American Journal of Psychiatry 152, 1831.
15. Berardi D, Amore M, Keck PE, Troia M, Dell' Atti M (1998). Clinical and pharmacological risk factors for neuroleptic malignant syndrome: a case control study. Biological Psychiatry 44, 748-754.
16. Bernstein R. (1979). Malignant neuroleptic syndrome: an atypical case. Psychosomatics 20, 840-846.
17. Blumer D (1997). Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings. Comprehensive Psychiatry 38, 193-201.
18. Bonwick RJ, Hopewood MJ, Morris PL (1996). Neuroleptic malignant syndrome and risperidone: a case-report. Australian and New Zealand Journal of Psychiatry 30, 419-421.
19. Bower DJ, Chalasani P, Ammons JC (1994). Withdrawal-induced neuroleptic malignant syndrome. American Journal of Psychiatry 151, 451-452.
20. Buckley PF (1996). Novel antipsychotics and neuroleptic malignant syndrome. Psychiatric Service 47, 431.
21. Buckley PF, Hutchinson M (1995). Neuroleptic malignant syndrome. Journal of Neurology, Neurosurgery and Psychiatry 58, 271-273.
22. Buckley PF, Meltzer HY (1995). Treatment of schizophrenia. In Schatzberg A, Nemeroff CD (Eds.), A Textbook of Psychopharmacology (pp. 615-639). Washington, DC: American Psychiatric Press.
23. Bush G, Fink M, Petrides G, Dowling F, Francis A (1996). Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavia 93, 129-136.
24. Caroff SN (1980). The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41, 79-83.
25. Caroff SN, Mann SC (1993). Neuroleptic malignant syndrome. Medical Clinics of North America 77, 185-202.
26. Caroff SN, Mann SC, Keck PE (1998). Specific treatment of the neuroleptic malignant syndrome. Biological Psychiatry 44, 378-381.
27. Caroff SN, Mann SC, Lazarus A (1987). Neuroleptic malignant syndrome (letter). Archives of General Psychiatry 44, 838-839.
28. Caroff SN, Mann SC, Lazarus A, Sullican K, Macfadden W (1991). Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Annals 21, 130-147.
29. Carr V (1983). The concept of clinical state in psychiatry: a review. Comprehensive Psychiatry 24, 370-391.
30. Catterson ML, Martin RL (1994). Anticholinergic toxicity masquerading as neuroleptic malignant syndrome: a case-report and review. Annals of Clinical Psychiatry 6, 267-269.
31. Clarke CE, Shand D, Yuill GM, Green MH (1988). Clinical spectrum of neuroleptic malignant syndrome. Lancet 2, 969-970.
32. Cohen BM, Baldessarini RJ, Pope HG, Lipinski JF (1985). Neuroleptic malignant syndrome (letter). New England Journal of Medicine 313, 1293.
33. Conlon P (1986). The spectrum concept of neuroleptic toxicity (letter). American Journal of Psychiatry 143, 811.
34. Darras M, Kakkouras L, Tuchman AJ, Koppel BS (1995). Rhabdomyolysis and hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome? Acta Neurologica Scandinavica 92, 161-165.
35. Das Gupta K, Young A (1991). Clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52, 105-107.
36. Dave M (1995). Two cases of risperidone-induced neuroleptic malignant syndrome. American Journal of Psychiatry 152, 1233-1234.
37. Delay J, Deniker P (1968). Drug-induced extrapyramidal syndromes. In Pinken D, Gruyn S (Eds.), Handbook of Clinical Neurology. New York: Elsevier, North Holland.
38. Deng MZ, Chen GQ, Phillops MR (1990). Neuroleptic malignant syndrome in 12 of 9792 Chinese inpatients exposed to neuroleptics: a prospective study. American Journal of Psychiatry 147, 1149-1155.
39. Dent J (1995). Catatonic syndrome following recovery from neuroleptic malignant syndrome. Journal of Intellectual Disability Research 39, 457-459.
40. Deuschl G, Oepen G, Hermle L (1987). Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 20, 168-170.
41. Dickey W (1991). The neuroleptic malignant syndrome. Progress in Neurobiology 36, 425-436.
42. Farde L, Nordstrom A-L, Wielsel F, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of c entral D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine; relation to extrapyramidal side-effects. Archives of General Psychiatry 49, 538-544.
43. Fink M (1995). Recognizing NMS as a type of catatonia. Journal of Neuropsychiatry, Neuropsychology and Behavioral Neurology 8, 75-76.
44. Fink M (1996a). Neuroleptic malignant syndrome and catatonia: one entity or two? Biological Psychiatry 39, 1-4.
45. Fink M (1996b). Toxin serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry 29, 159-161.
46. Fricchione GL (1985). Neuroleptic catatonia and its relationship to psychogenic catatonia. Biological Psychiatry 20, 304-313.
47. Friedman JH, Davis R, Wagner RL (1988). Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clinical Neuropharmacology 11, 373-377.
48. Fogel BS, Goldberg RJ (1985). Neuroleptic malignant syndrome (letter). New England Journal of Medicine 313, 1292.
49. Goates MG, Escobar JI (1992). An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge (letter). Journal of Clinical Psychopharmacology 12, 139-140.
50. Goldwasser HD, Hooper JF, Spears NM (1989). Concomitant treatment of neuroleptic malignant syndrome and psychosis. British Journal of Psychiatry 154, 102-104.
51. Gurrera RJ, Chang SS, Romero JA (1992). A comparison of diagnostic criteria for neuroleptic malignant syndrome. Journal of Clinical Psychiatry 53, 56-62.
52. Guze BH, Baxter LR (1985). Neuroleptic malignant syndrome (letter). New England Journal of Medicine 313, 1293.
53. Haggerty JJ, Bensten BS, Gillette GM (1987). Neuroleptic malignant syndrome superimposed on tardive dyskinesia. British Journal of Psychiatry 150, 104-105.
54. Harsch HH (1987). Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine case. Journal of Clinical Psychiatry 48, 328-333.
55. Hasan S, Buckley P (1998). Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. American Journal of Psychiatry 155, 1113-1116.
56. Howells R (1994). Neuroleptic malignant syndrome. Don't confuse with anticholinergic intoxication. British Medical Journal 308, 200-201.
57. Hynes AF, Vickar EL (1996). Case-study: neuroleptic malignant syndrome without pyrexia. Journal of the American Academy of Children and Adolescent Psychiatry 35, 959-962.
58. Illing M, Ancill R (1996). Clozapine-induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS. Canadian Journal of Psychiatry 41, 258.
59. Itoh H, Ohtsuka N, Ogita K, Yagi G, Muira S, Koga Y (1979). Malignant neuroleptic syndrome - its present status in Japan and clinical problems. Folia Psychiatrica et Neurologia 31, 565-576.
60. Iwahashi K (1994). CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biological Psychiatry 36, 780-782.
61. 123I]iodobenzamide single-photon-emission-computed tomography in neuroleptic malignant syndrome. Movement Disorders 11, 726-728.
62. Kawanishi C, Hanihara T, Shimoda Y, Suzuki K, Sugiyama N, Onishi H, Miyakawa T, Yamada Y, Kosaka K (1998). Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5HT1A and 5HT2A receptor genes. American Journal of Psychiatry 155, 1275-1277.
63. Kraupl Taylor F (1983). A logical analysis of disease concepts. Comprehensive Psychiatry 24, 35-48.
64. Keck PE Jr, Sebastianelli J, Pope HG Jr, McElroy SL (1989). Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Journal of Clinical Psychiatry 50, 352-355.
65. Kellam AMP (1987). The neuroleptic malignant syndrome, so-called: a survey of world literature. British Journal of Psychiatry 150, 752-759.
66. Kellam AMP (1990). The frequency of neuroleptic malignant syndrome. British Journal of Psychiatry 157, 167-173.
67. Kendell RE (1989), Clinical validity. Psychological Medicine 19, 45-55.
68. Kurlan R, Hamill R, Shoulson I (1984). Neuroleptic malignant syndrome: review. Clinical Neuropharmacology 7, 109-120.
69. Lazarus A, Lipschutz (1991). Further observations on the neuroleptic malignant syndrome (letter). Journal of Clinical Psychopharmacology 2, 148-149.
70. Lazarus A, Mann SC, Caroff SN (1989). The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC: American Psychiatric Press.
71. Lev R, Clark RF (1994). Neuroleptic malignant syndrome presenting without fever: case report and review of literature. Journal of Emergency Medicine 12, 49-55.
72. Levenson JL (1985). Neuroleptic malignant syndrome. American Journal of Psychiatry 142, 1137-1145.
73. Levenson JL (1986). Reply to: Diagnosing and treating neuroleptic malignant syndrome. American Journal of Psychiatry 143, 675.
74. Levin GM, Lazowick AL, Powell HS (1996). Neuroleptic malignant syndrome with risperidone. Journal of Clinical Psychopharmacology 16, 192-193.
75. Levinson DF, Simpson GM (1986). Neuroleptic-induced extrapyramidal symptoms with fever heterogeneity of neuroleptic malignant syndrome. Archives of General Psychiatry 43, 839-848.
76. Looi JC, Cubis JC, Saboisjy J (1995). Hyponatremia, convulsions and neuroleptic malignant syndrome in a male with schizo-affective disorder. Australian and New Zealand Journal of Clinical Psychiatry 52, 99-101.
77. Manor I, Hermesh H, Munitz H, Weizman A (1997). Neuroleptic malignant syndrome with gangliosidosis type II. Biological Psychiatry 41, 1222-1224.
78. Mezaki T, Ohtani SI, Abe K, Hirono M, Udaka F, Kameyama M (1989). Benign type of malignant syndrome. Lancet 1, 49-50.
79. Miller DD, Melhem JA, Sharafuddin MD, Kathol RG (1991). A case of clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52, 99-101.
80. Misiaszek JJ, Potter RL (1985). Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 26, 62-66.
81. Miyaoka H, Kamijima K (1995). Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? International Clinical Psychopharmacology 10, 265-267.
82. Modestein J, Toffler G, Drescher JP (1992). Neuroleptic malignant syndrome: results of a prospective study. Psychiatry Research 44, 148-151.
83. Muller T, Becker T, Fritze J (1988). Neuroleptic malignant syndrome after clozapine plus carbamazine. Lancet 2, 1500.
84. Murray S, Haller E (1995). Risperidone and NMS? Psychiatric Services 46, 951.
85. Najara JE, Enikeev TD (1995). Risperidone and neuroleptic malignant syndrome: a case report. Journal of Clinical Psychiatry 56, 534-535.
86. Newman M, Adityanjee, Jampala VC (1997). Atypical neuroleptic malignant syndrome associated with risperidone treatment. American Journal of Psychiatry 154, 1475.
87. Nierenberg D, Disch M, Manheimer E, Patterson J, Ross J, Silvestri G, Summerhill E (1991). Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clinical Pharmacology and Therapeutics 50, 580-586.
88. Nopoulos P, Flaum M, Miller DD (1990). Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Annals of Clinical Psychiatry 2, 251-253.
89. Ochi G, Watanabe K, Tokuoka H, Hatakenaka S, Arai T (1995). Neuroleptic malignant-like syndrome: a complication of acute organophosphate poisoning. Canadian Journal of Anaesthesia 42, 1027-1030.
90. O'Dwyer AM, Sheppard NP (1993). The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychological Medicine 23, 323-326.
91. Ossemann M, Sindic CJ, Laterre C (1996). Tetrabenazine as a cause of neuroleptic malignant syndrome (letter). Movement Disorders 11, 95.
92. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1991). Is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry 158, 850-853.
93. Peele R, De Veau L, Zanni G (1988). Hyperthermic catatonia (letter). Hospital and Community Psychiatry 39, 83.
94. Pelonero AL, Levenson JL, Pandurangi AK (1998). Neuroleptic malignant syndrome: a review. Psychiatric Services 49, 1163-1172.
95. Pope HG, Check PE, Miserly SL (1986a). Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 143, 1227-1233.
96. Pope HG, Cole JO, Choras PT, Fulwiler CE (1986b). Apparent neuroleptic malignant syndrome with clozapine and lithium. Journal of Nervous and Mental Disease 174, 493-495.
97. Raja M, Altavista MC, Cavallari S, Lubich L (1994). Neuroleptic malignant syndrome and catatonia. A report of three cases. European Archives of Psychiatry and Clinical Neurosciences 243, 299-303.
98. Ram A, Cao Q, Keck PE, Pope HG, Otani K, Addonizio G, McElroy SL, Kaneko S, Redichova M, Gershon ES, Gejman PV (1995). Structural change in the dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. American Journal of Medical Genetics 60, 228-230.
99. Reddig S, Minnema AM, Tandon R (1993). Neuroleptic malignant syndrome and clozapine. Annals of Clinical Psychiatry 5, 25-27.
100. Robins E, Guze SG (1970). Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry 126, 225-242.
101. Rosebush P, Stewart T (1989). A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 146, 717-725.
102. Rosenberg J, Pentel P, Pond S, Benowitz N, Olson K (1986). Hyperthermia associated with drug intoxication. Critical Care Medicine 14, 964-969.
103. Rosenberg MR, Green M (1989). Neuroleptic malignant syndrome: review of response to treatment. Archives of Internal Medicine 149, 1927-1931.
104. Roth SD, Addonizio G, Susman VL (1986). Diagnosing and treating neuroleptic malignant syndrome (letter). American Journal of Psychiatry 143, 673.
105. Sacco RL, VanGool R, Mohr JP, Hauser WA (1990). Nontraumatic coma: Glasgow coma score and coma etiology as predictor of 2-week outcome. Archives of Neurology 47, 1181-1184.
106. Sachdev P, Kruk J, Kneebone M, Kissane D (1995). Clozapine induced neuroleptic malignant syndrome: review and report of new cases. Journal of Clinical Psychopharmacology 15, 365-371.
107. Sakkas PN, Davis JM, Hua J, Wang S (1991). Pharmacotherapy of neuroleptic malignant syndrome. Psychiatric Annals 21, 157-164.
108. Schooler NR, Kane JM (1983). Research diagnoses for tardive dyskinesia (letter). Archives of General Psychiatry 39, 486-487.
109. Shalev A, Munitz H (1986). The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica 73, 337-347.
110. Sharma R, Trappler B, Ng YK, Leeman CP (1996). Risperidone-induced neuroleptic malignant syndrome. Annals of Pharmacotherapy 30, 775-775.
111. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica 212, 11-19.
112. Simpson GM, Davis GC (1984). Case report of neuroleptic malignant syndrome associated with withdrawal of amantidine. American Journal of Psychiatry 141, 796-797.
113. Singer S, Richard C, Boland RJ (1995). Two cases of risperidone-induced neuroleptic malignant syndrome (letter). American Journal of Psychiatry 152, 1234.
114. Singh G (1981). The malignant neuroleptic syndrome. A review with report of three cases. Indian Journal of Psychiatry 23, 179-183.
115. Spitzer LR, Williams JBW (1985). Classification of mental disorders. In Kaplan HI, Saddock BJ (Eds.), Comprehensive Textbook of Psychiatry, 4th ed. (pp. 591-612). Baltimore/Philadelphia: Williams & Wilkins.
116. Taniguchi N, Tanii H, Nishikawa T, Miyamae Y, Shinozaki K, Inoue Y, Morihara T, Nakano Y, Nishimura T, Takeda M (1997). Classification system of complications in neuroleptic malignant syndrome. Methods and Findings in Experimental Clinical Pharmacology 19, 193-199.
117. Tarsy D (1996). Risperidone and neuroleptic malignant syndrome. Journal of the American Medical Association 275, 446.
118. Teasdale G, Jennette B (1974). Assessment of coma and impaired consciousness: a practical scale. Lancet 2, 81-84.
119. Thornberg SA, Ereshefsky L (1993). Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 13, 510-514.
120. Toru M, Matsuda O, Makiguchi K, Sugano K (1977). Neuroleptic malignant syndrome like state following withdrawal of antiparkinsonian drugs. Journal of Nervous and Mental Diseases 169, 324-327.
121. Tsai G, Crisostomo G, Rosenblatt ML, Stern TA (1995). Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 7, 91-95.
122. Van Putten T, Beckson M, Marder SR (1988). The neuroleptic malignant syndrome manifested as a prolonged confusional state. Journal of Clinical Psychopharmacology 8, 229-230.
123. Velamoor VR, Fernando MLD, Williamson P (1990). Incipient neuroleptic malignant syndrome? British Journal of Psychiatry 156, 581-584.
124. Velamoor VR, Norman RMG, Caroff SN, Mann SC, Sullivan KA, Antelore (1994). Progression of symptoms in neuroleptic malignant syndrome. Journal of Nervous and Mental Diseases 182, 168-173.
125. Velamoor VR, Swamy GN, Parmar RS (1992). Confusion, agitation and rigidity: early signs of NMS. Canadian Journal of Psychiatry 37, 280.
126. Walker WD (1988). Spectrum concept of neuroleptic malignant syndrome (letter). British Journal of Psychiatry 153, 574.
127. Webster P, Wijeratne C (1994). Risperidone-induced neuroleptic malignant syndrome (letter). Lancet 344, 1228-1229.
128. Weller M, Kornhuber J (1993). Does clozapine cause neuroleptic malignant syndrome? Journal of Clinical Psychiatry 54, 70-71.
129. Weller M, Kornhuber J (1996). Clozapine-induced neuroleptic malignant syndrome: another inconclusive case-report (letter). Australian and New Zealand Journal of Medicine 26, 232-233.
130. Weinberg SE, Twerski RS (1983). Neuroleptic malignant syndrome. Anesthesia and Analgesia 62, 848-850.
131. Wetli CV, Mash D, Karch SB (1996). Cocaine associated agitated delirium and the neuroleptic malignant syndrome. American Journal of Emergency Medicine 14, 425-428.
132. White DAC, Robins AH (1991). Catatonia: harbinger of the neuroleptic malignant syndrome. British Journal of Psychiatry 158, 419-421.
133. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann K J, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M, Basavaraju N (1991). The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology 11, 34-42.
134. Wong MM (1996). Neuroleptic malignant syndrome: two cases without muscle rigidity. Australian and New Zealand Journal of Psychiatry 30, 415-418.
135. Woodbury MM, Woodbury MA (1992). Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. Journal of American Academy of Child and Adolescent Psychiatry 31, 1161-1164.
136. World Health Organization (1992). Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. Appendix Chapter VI: Diseases of the Nervous System. Geneva: WHO.